Navigation Links
Psoriasis in Medical Technology

SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

... with inflamed, scaly, red patches of skin psoriasis and psoriasis nail involvement. Symptoms may include stiffness ... feet, lower back and neck are commonly affected. psoriasis affects an estimated two to three percent of the ...

Innovative Psoriasis Treatment PSORENT(R) Announces Healthcare Cost Savings Potential Consistent with President Obama's Announcement on Healthcare Reform

... company in New Jersey that's done the same for psoriasis sufferers of all ages." Mr. Steele is ... associated with their non-prescription, psoriasis medicine PSORENT(R) psoriasis topical solution. Earlier this week, ...

Two-Year Data Show Patients Receiving SIMPONI(TM) (golimumab) Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis and Ankylosing Spondylitis

... than three percent Body Surface Area (BSA) psoriasis skin involvement at baseline (n=296) were ... with inflamed, scaly, red patches of skin psoriasis and psoriasis nail involvement. Symptoms may include stiffness ...

Galderma Announces Interim Data Relating to Sequential Treatment Regimen of Clobex(R) Spray Followed by Vectical(TM) Ointment in Managing Plaque Psoriasis

... from a study of sequential treatment of plaque psoriasis using Clobex (R) (clobetasol propionate) Spray ... indicate that sequential treatment of plaque psoriasis with Clobex Spray followed by Vectical Ointment is effective in managing plaque psoriasis over a 12-week period. Additionally, the interim ...

Dermatologists Caution That Severe Cases of Psoriasis Can Be Associated With Other Serious Medical Conditions

... surface, the thick, red, scaly, itchy plaques of psoriasis -- which have been shown to have a significant ... However, a growing body of research suggests that psoriasis patients are at an increased risk of developing ... disease and diabetes, particularly when their psoriasis is severe. Speaking today at the 67th Annual ...

Scientists Unmask Genetic Markers Associated With Psoriasis

... scientists reveal DNA 'hotspots' linked to psoriasis ANN ARBOR, Mich., Jan. 25 ... IL-23 pathway are already targeted by effective psoriasis therapies. Others, like TNFAIP3 and TNIP1, may become targets for the psoriasis treatments of the future." ...

Synvista Therapeutics Announces First Dosing of SYI-2074 in Clinical Trial for Psoriasis

... the treatment of chronic, mild-to-moderate plaque psoriasis in adults. The trial is being conducted in three ... to expand the scope of treatment modalities for psoriasis following this trial and look forward to ... can be inhibited by SYI-2074. About psoriasis ...

CHMP Recommends Approval of New Indication for Enbrel(R) as Treatment for Severe Psoriasis in Paediatric Patients

... the first biologic treatment indicated for severe psoriasis in children and adolescents. Enbrel is currently ... for the treatment of moderate-to-severe plaque psoriasis in adults, as well as for ankylosing spondylitis, ... similar for Enbrel and placebo. Impact of psoriasis Across Europe, 5.1 million people are ...

Continuous Treatment With Abbott's HUMIRA(R) Achieves Superior Long-Term Efficacy for Psoriasis Patients Compared to Interrupting Treatment

... Treats Adult Patients with Moderate to Severe psoriasis Regardless of Age, Duration of Disease, ... PARIS, Sept. 18 /PRNewswire-FirstCall/ -- More psoriasis patients achieve efficacy when they receive ... Every Other Week in Moderate to Severe psoriasis Trial) and the period of open-label treatment ...

FDA Advisory Committee Unanimously Recommends Approval of Ustekinumab for Treatment of Moderate to Severe Plaque Psoriasis

... Clinical, Centocor R&D. "For many patients, psoriasis is a serious disease, and they are in need of ... the drug are made by the FDA. About Psoriasis psoriasis is a chronic, immune-mediated disease, caused by ... Europeans. Nearly one-quarter of people with psoriasis have cases that are considered moderate to ....

Anacor Pharmaceuticals Announces Positive Results from Phase 2a Clinical Trial of AN2728 in Psoriasis Patients

... with psoriasis commonly have similar areas of psoriasis on their left and right, or front and back sides. ... trial, 35 patients treated one of their areas of psoriasis with AN2728 ointment, and a matching area on ... approximately 10 million people worldwide, psoriasis is an inflammation of the skin caused by a ...

REMICADE-Treated Patients Experienced Rapid and Substantial Improvement in Psoriasis in Critical Regions of Body

... showed patients with moderate to severe plaque psoriasis receiving REMICADE(R) (infliximab) achieved ... clinical trials evaluated, the Study of psoriasis with Infliximab [REMICADE] Induction Therapy ... (EXPRESS), and the Evaluation of Infliximab for psoriasis in a [REMICADE] Efficacy and Safety Study ...

Ustekinumab (CNTO 1275) Phase 3 Data Show Long-Term Improvement Of Chronic Plaque Psoriasis

... Ustekinumab Maintained Improvement from psoriasis Through One Year SAN ... in the treatment of moderate to severe plaque psoriasis through one year. According to findings presented ... sustained at least a 75 percent improvement in psoriasis through one year, as measured by the ...

Abbott's HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis

... patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy ... disease in 2007. "The approval of HUMIRA for psoriasis is welcome news for people living with this ... Pam Field, acting president and CEO, National psoriasis Foundation. "We are pleased to let people ...

Rigel Announces Initiation of Phase 1 Clinical Trial of R348 for Rheumatoid Arthritis, Psoriasis and Other Immune Disorders

... for patients with rheumatoid arthritis (RA), psoriasis and other immune disorders. In preclinical ... swelling. It has also shown efficacy in models of psoriasis and transplant rejection. This is Rigel's fourth ... debilitating and degenerative autoimmune disease. psoriasis affects approximately 7.5 million in the U.S. and ...

Study Linking Increased Risk of Death to Severe Psoriasis a Call to Action

... National psoriasis Foundation urges psoriasis patients to take control of their health, help ... week showing that people with severe psoriasis are likely to have a shorter life expectancy ...

Centocor and Janssen-Cilag Submit Applications Requesting Approval of Ustekinumab in the U.S. and Europe for Treatment of Moderate to Severe Plaque Psoriasis

... Europeans. Nearly one-quarter of people with psoriasis have cases that are considered moderate to ... who achieved at least a 75 percent reduction in psoriasis as measured by the psoriasis Area and Severity Index (PASI 75). "We are very ...

Phase 3 Data Show New Anti-TNF, Golimumab, Significantly Improved Arthritis, Skin and Nail Manifestations in Patients with Psoriatic Arthritis

... disease (as measured by a 75 percent reduction in psoriasis Area and Severity Index [PASI 75] in patients with baseline body surface area with psoriasis of at least three percent, and the Nail psoriasis Severity Index [NAPSI]). Golimumab, Centocor ....

Promising Phase 3 Trial Results Show Novel Biologic Therapy Ustekinumab (CNTO 1275) Significantly Improved Psoriasis

... of patients with moderate to severe plaque psoriasis receiving two doses of ustekinumab (CNTO 1275) achieved at least a 75 percent reduction in psoriasis at week 12, the primary endpoint of the study, as measured by the psoriasis Area and Severity Index (PASI 75). ...

Abbott's ABT-874 Shows Positive Results for Maintenance of Response in Phase II Psoriasis Study

... Study Data Show Patients with Moderate to Severe psoriasis Who Responded to Anti-IL-12/23 ABT-874 after 12 ... who achieved 75 percent improvement in psoriasis signs and symptoms (PASI 75) at 12 weeks stopped ... 90 percent of patients with moderate to severe psoriasis achieved 75 percent improvement ...

Pivotal Ustekinumab (CNTO 1275) Phase 3 Data to Debut at World Congress of Dermatology Meeting

... in the treatment of moderate to severe plaque psoriasis will be presented for the first time at the 21st ... for the treatment of moderate to severe plaque psoriasis and is being investigated as an ... countries outside of the United States. About psoriasis ...

New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study

... (PsA), ulcerative colitis (UC), pediatric Crohn's disease (PCD) and psoriasis (PsO). The safety and efficacy of REMICADE have been well established in ... Crohn's disease, ankylosing spondylitis, psoriatic arthritis or plaque psoriasis for a long time, particularly those with highly active disease may be more ...

Study Reveals Novel LCD Solution Provides Significant Benefits Versus Calcipotriol In Treatment Of Moderate Psoriasis

... developed Psorent to answer patient needs for a non-prescription topical psoriasis therapy that offers a different experience from traditional coal tar ... this study validates our success in creating this new-generation topical psoriasis therapy that offers clinical efficacy in an aesthetically pleasing ...

BioCryst Reports Positive Preliminary Results of a Shionogi & Co., Ltd. Sponsored Phase II Study of I.V. Peramivir for the Treatment of Influenza in the Outpatient Setting

... commercialization including forodesine HCl in oncology, BCX-4208 in psoriasis and peramivir in seasonal and life-threatening influenza. BioCryst is ... (CTCL) may not meet its endpoint, that the Phase II trial of BCX-4208 for psoriasis may not be successfully completed, that development and commercialization ...

BioCryst Announces Initiation of Phase II Study of Intramuscular Peramivir for the Treatment of Seasonal Influenza

... commercialization including forodesine HCl in oncology, BCX-4208 in psoriasis and peramivir in seasonal and life-threatening influenza. BioCryst is ... (CTCL) may not meet its endpoint, that the Phase II trial of BCX-4208 for psoriasis may not be successfully completed, that development and commercialization ...

Synvista Therapeutics Reports Results of Three Phase 2 Clinical Trials of SYI-2074 in Diabetic Patients with Cardiovascular Disease

... expects to begin enrollment of patients with mild-to-moderate plaque psoriasis in a Phase 2 trial in the third quarter of 2008, as originally planned. ... inflammation related to oxidative stress. It currently plans a program in psoriasis with its lead compound. The Company is developing a clinical diagnostic ...

New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease

... (PsA), ulcerative colitis (UC), pediatric Crohn's disease (PCD) and psoriasis (PsO). The safety and efficacy of REMICADE have been well established in ... Crohn's disease, ankylosing spondylitis, psoriatic arthritis or plaque psoriasis for a long time, particularly those with highly active disease may be more ...

Cytokine PharmaSciences Initiates Phase I Study of Oral Anti-Inflammatory Agent, CPSI-2364

... An intravenous formulation of semapimod was shown to have significant anti-inflammatory activity in Phase II clinical trials in Crohn's disease, psoriasis and ERCP-induced pancreatitis. However, that formulation caused dose-limiting local reactions, such as phlebitis. To overcome this problem, the ...

New One-Year Data from REMICADE(R) SONIC Trial Show Sustained Efficacy Compared with Azathioprine in Treatment of Crohn's Disease

... (CD), rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA), ulcerative colitis (UC), pediatric Crohn's disease (PCD) and psoriasis (PsO). The safety and efficacy of REMICADE have been well established in clinical trials over the past 16 years and through commercial experience ...

QuatRx Completes Enrollment of Ophena(TM)(Ospemifene Tablets) Final Pivotal Phase 3 Study in Women with Postmenopausal Vaginal Atrophy

... in Phase 1 as a potential treatment for dyslipidemia. Becocalcidiol, a novel Vitamin D analogue, is in Phase 2 clinical trials for the treatment of psoriasis through QuatRx's partner, Galderma. QuatRx's preclinical program is designed to address sex steroid dependent diseases through inhibition of ...

Video: Provectus PV-10 Interim Phase 2 Safety and Efficacy Results are as Good as or Better than Phase 1 Results

... currently conducting Phase 2 clinical trials of its proprietary drugs PV-10 as a therapy for metastatic melanoma and PH-10 as a topical treatment for psoriasis and atopic dermatitis. Information about these and the Company's other clinical trials can be found at the NIH registry, www.clinicaltrials.gov . ...

Forest Laboratories, Inc. and Laboratorios Almirall, S.A. Provide an Update on the Aclidinium Bromide Clinical Development Program

... research resources are related to the treatment of asthma, COPD (Chronic Obstructive Pulmonary Disease), rheumatoid arthritis, multiple sclerosis, psoriasis and dermatology in general. Almirall is currently present in over 70 countries with direct presence in Europe and Latin America through 11 ...

Study Finds Family History, Higher Incidence of Sunburns Associated With Rosacea

... as well as explore whether rosacea was predictive of other systemic conditions that might be related -- similar to the link between severe cases of psoriasis and other medical conditions such as diabetes and heart disease." In this case-controlled study that built on the photo study conducted at ...

Synvista Therapeutics Announces Termination of Clinical Trials of Alagebrium and SYI-2074 and Provides Business Update

... with diastolic heart failure; and - the Phase 2 trial of a topical formulation of SYI-2074 for the treatment of chronic, mild-to-moderate plaque psoriasis in adults. Each of these trials will be terminated as promptly as possible. As noted previously, the Company has submitted an application ...

Merck Serono Announces Initiation of the ORACLE MS Trial to Evaluate Cladribine Tablets in Patients at Risk of Developing Multiple Sclerosis

... infertility (Gonal-f(R)), endocrine and cardiometabolic disorders (Glucophage(R), Concor(R), Euthyrox(R), Saizen(R), Serostim(R)), as well as psoriasis (Raptiva(R)). With an annual R&D expenditure of around EUR 1bn, Merck Serono is committed to growing its business in specialist-focused therapeutic ...

Merck Serono Completes Enrollment in the REFLEX Trial of Rebif(R) in Patients at Risk of Developing Multiple Sclerosis

... infertility (Gonal-f(R)), endocrine and cardiometabolic disorders (Glucophage(R), Concor(R), Euthyrox(R), Saizen(R), Serostim(R)), as well as psoriasis (Raptiva(R)). With an annual R&D expenditure of around EUR 1bn, Merck Serono is committed to growing its business in specialist-focused therapeutic ...

QuatRx Initiates Second Phase 3 Study of Ophena(TM) (Ospemifene Tablets) in Women With Postmenopausal Vaginal Syndrome

... in Phase 1 as a potential treatment for dyslipidemia. Becocalcidiol, a novel Vitamin D analogue, is in Phase 2 clinical trials for the treatment of psoriasis through QuatRx's partner, Galderma. QuatRx's preclinical program is designed to address sex steroid dependent diseases through inhibition of ...

Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD)

... research resources are related to the treatment of asthma, COPD (Chronic Obstructive Pulmonary Disease), rheumatoid arthritis, multiple sclerosis, psoriasis and dermatology in general. Almirall is currently present in over 70 countries with direct presence in Europe and Latin America through 11 ...

ASPIRE Independent Review Board Announces 10 Ways to Protect Participants' Rights in Clinical Drug Trials and Optimize Results From Research

... Cancer were instrumental in extending my life," states Mercie Madrid. Another participant, Mike Means, says, "I participated in a clinical trial for psoriasis and my condition improved dramatically." ASPIRE IRB's 10 Ways to Protect Participants' Rights and Maximize Results for Clinical Research 1) ...

Abbott Presents Long-Term Data From Extension Study Showing Adult Crohn's Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission

... in patients with active ankylosing spondylitis. HUMIRA is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. HUMIRA should only be ...
Other Contents
(Date:7/13/2014)... more effective treatments for cachexia, a profound wasting of ... cancer patients, raising their risk of death, according to ... been tried to reverse the condition, which may cause ... but none have had great success. , Scientists reporting ... Nature , led by Bruce Spiegelman, PhD, demonstrated that ...
(Date:7/11/2014)... The Mills Canyon fire started near the City of ... of local resources, the fire quickly grew to over ... cause of the fire is under investigation by the ... is working with existing local resources in developing fire ... Forest Service (USFS), Washington State Department of Natural Resources, ...
(Date:7/11/2014)... Cell scientists have set a "mouse TRAP" to capture ... a recent study published in the Journal of ... a technique called TRAP to extract cellular and genetic ... by scientists at the Rockefeller Institute for Medical Research ... the protein-making machinery, or ribosomes, of the cell type ...
Breaking Biology News(10 mins):Antibody halts cancer-related wasting condition 2Antibody halts cancer-related wasting condition 3
(Date:7/14/2014)... Wellesley, Mass. (PRWEB) July 14, 2014 ... its new report, SYNTHETIC BIOLOGY: GLOBAL MARKETS ... to grow to nearly $11.9 billion in 2018, ... of 34.4%. Enabled products account for the fastest ... and 36.7% CAGR. Synthetic biology-enabled products in the ...
(Date:7/14/2014)... SUNDAY, July 13, 2014 (HealthDay News) -- Along with ... people with Alzheimer,s disease and other types of dementia, ... their quality of life, the researchers said. "These ... variety of benefits for people with dementia and their ... Lerner, of Case Western Reserve University and University Hospitals ...
(Date:7/14/2014)... 14, 2014 (HealthDay News) -- Stress can slow a woman,s ... The study included 58 women, average age 53, who were ... given a meal than included 930 calories and 60 grams ... it took the women to burn off those calories and ... stressful events during the previous 24 hours burned 104 fewer ...
(Date:7/14/2014)... July 14, 2014 Skin ... its Grand Opening on Monday, July 14th, located ... The celebration will last all week through Saturday, ... patients. Everyone is welcomed to attend. The business ... provides physician-administered skincare, anti-aging, weight loss services, and ...
(Date:7/14/2014)... California (PRWEB) July 14, 2014 ... to reach USD 4,285.1 million by 2020 growing ... new study by Grand View Research, Inc. Steady ... biology for bioinformatics R&D programs designed for sequencing ... number of clinical studies in pharmacogenomics and pharmacokinetics ...
Breaking Medicine News(10 mins):Health News:Global Market for Synthetic Biology to Reach Nearly $11.9 Billion by 2018 — Enabled Products Account for the Fastest Growing Segment with 36.7% CAGR 2Health News:Global Market for Synthetic Biology to Reach Nearly $11.9 Billion by 2018 — Enabled Products Account for the Fastest Growing Segment with 36.7% CAGR 3Health News:Cataract Surgery a Plus for Someone With Dementia, Study Says 2Health News:Stress May Leave You Heading to the Cookie Jar 2Health News:The Cosmetic Medic Announces Grand Opening of New Skin M.D., a Physician-Administered Anti-aging, Skincare, and Weight Loss Practice 2Health News:The Cosmetic Medic Announces Grand Opening of New Skin M.D., a Physician-Administered Anti-aging, Skincare, and Weight Loss Practice 3Health News:Global Computational Biology Market by Application (Cellular & Biological Simulation), by Services (In-house, Contract) is Expected to Reach USD 4,285.1 Million by 2020 2Health News:Global Computational Biology Market by Application (Cellular & Biological Simulation), by Services (In-house, Contract) is Expected to Reach USD 4,285.1 Million by 2020 3Health News:Global Computational Biology Market by Application (Cellular & Biological Simulation), by Services (In-house, Contract) is Expected to Reach USD 4,285.1 Million by 2020 4Health News:Global Computational Biology Market by Application (Cellular & Biological Simulation), by Services (In-house, Contract) is Expected to Reach USD 4,285.1 Million by 2020 5Health News:Global Computational Biology Market by Application (Cellular & Biological Simulation), by Services (In-house, Contract) is Expected to Reach USD 4,285.1 Million by 2020 6
Other TagsOther Tags